Q4/2024 12/31/2024 EPS -0.170 ZacksConsensus -0.150 ActVsEst (0.020) - Miss

Akoya BioSciences, Inc. (AKYA)
Company Research
Source: Wall Street Horizon

Impact Snapshot
Event Time:
AKYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKYA alerts
High impacting Akoya BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
AKYA
News
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, AKYA, CKPT, QTRX on Behalf of ShareholdersGlobeNewswire
- $HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – BRDG, AKYA, CKPT, QTRXGlobeNewswire
- Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at Piper Sandler from $2.40 to $1.65. They now have a "neutral" rating on the stock.MarketBeat
- STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - OPTN, SLRN, AKYA, SHYFPR Newswire
- Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer InequitiesGlobeNewswire
AKYA
Earnings
- 3/17/25 - Miss
AKYA
Sec Filings
- 4/15/25 - Form DEFM14A
- 4/4/25 - Form 425
- 4/4/25 - Form 8-K
- AKYA's page on the SEC website